IFN is an antiviral agent approved for the treatment of CHB and chronic hepatitis C. Although IFN monotherapy has been ineffective in treating HBV/HCV dually infected patients [13], the introduction of ribavirin in combination with IFN-α or pegylated IFN-α for HBV/HCV dually infected patients has been shown to be as effective for patients with HCV monoinfection in terms of sustained eradication of HCV viremia [14], [15]. The gene discussed is IFNA1; the disease is chronic hepatitis C virus infection.